Encyclopedia of Signaling Molecules

2018 Edition
| Editors: Sangdun Choi

Epidermal Growth Factor Receptor

  • Brian P. CeresaEmail author
  • Julie A. Gosney
  • Nicole M. Jackson
  • Jamie S. Rush
Reference work entry
DOI: https://doi.org/10.1007/978-3-319-67199-4_101589


Historical Background

The epidermal growth factor receptor (EGFR, also known as ErbB1) is the first of four members of the ErbB lineage of receptor tyrosine kinases. The ErbB family members are cell surface receptors that are expressed in most tissues throughout the body and form both homo- and heterodimers to generate signals. Heterodimers form with the other ErbB family members. For example, ErbB2 (which lacks endogenous ligands) and ErbB3 (known to have reduced kinase activity) heterodimers provide a foundation for the most robust signaling network of the ErbB family. ErbB4 is structurally similar to ErbB1 and ErbB3, but is unique in that it is the only ErbB family member capable of signaling directly from within the nucleus. EGFR is one of the most well-studied cell surface receptor...

This is a preview of subscription content, log in to check access.


  1. Bhargava R, Gerald WL, Li AR, Pan Q, Lal P, Ladanyi M, et al. EGFR gene amplification in breast cancer: correlation with epidermal growth factor receptor mRNA and protein expression and HER-2 status and absence of EGFR-activating mutations. Mod Pathol. 2005;18:1027–33.  https://doi.org/10.1038/modpathol.3800438.CrossRefPubMedGoogle Scholar
  2. Bogdanowicz BS, Hoch MA, Hartranft ME. Flipped script for gefitinib: a reapproved tyrosine kinase inhibitor for first-line treatment of epidermal growth factor receptor mutation positive metastatic nonsmall cell lung cancer. J Oncol Pharm Pract. 2016;  https://doi.org/10.1177/1078155216634179.CrossRefPubMedGoogle Scholar
  3. Carpenter G, Cohen S. Epidermal growth factor. J Biol Chem. 1990;265:7709–12.PubMedGoogle Scholar
  4. Ceresa BP. Spatial regulation of epidermal growth factor receptor signaling by endocytosis. Int J Mol Sci. 2012;14:72–87.  https://doi.org/10.3390/ijms14010072.CrossRefPubMedPubMedCentralGoogle Scholar
  5. Ceresa BP, Peterson JL. Cell and molecular biology of epidermal growth factor receptor. Int Rev Cell Mol Biol. 2014;313:145–78.  https://doi.org/10.1016/B978-0-12-800177-6.00005-0.CrossRefPubMedGoogle Scholar
  6. Chen JC, Zeng FH, Forrester SJ, Eguchi S, Zhang MZ, Harris RC. Expression and function of the epidermal growth factor receptor in physiology and disease. Physiol Rev. 2016;6:1025–69.CrossRefGoogle Scholar
  7. Ciardiello F, Tortora G. EGFR antagonists in cancer treatment. N Engl J Med. 2008;358:1160–74.  https://doi.org/10.1056/NEJMra0707704.CrossRefPubMedGoogle Scholar
  8. Dancer J, Takei H, Ro JY, Lowery-Nordberg M. Coexpression of EGFR and HER-2 in pancreatic ductal adenocarcinoma: a comparative study using immunohistochemistry correlated with gene amplification by fluorescencent in situ hybridization. Oncol Rep. 2007;18:151–5.PubMedGoogle Scholar
  9. Du J, Wilson PD. Abnormal polarization of EGF receptors and autocrine stimulation of cyst epithelial growth in human ADPKD. Am J Phys. 1995;269:C487–95.CrossRefGoogle Scholar
  10. Estrada C, Villalobo A. Epidermal growth factor receptor in the adult brain. In: Janigro D, editor. Cell cycle in the central nervous system. Totowa: Humana Press Inc.; 2006. p. 265–77.CrossRefGoogle Scholar
  11. Fowler KJ, Walker F, Alexander W, Hibbs ML, Nice EC, Bohmer RM, et al. A mutation in the epidermal growth factor receptor in waved-2 mice has a profound effect on receptor biochemistry that results in impaired lactation. PNAS (USA). 1995;92:1465–9.CrossRefGoogle Scholar
  12. Kohler J, Schuler M. Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: a review. Onkologie. 2013;36:510–8.  https://doi.org/10.1159/000354627.CrossRefPubMedGoogle Scholar
  13. Kuan CT, Wikstrand CJ, Bigner DD. EGF mutant receptor vIII as a molecular target in cancer therapy. Endocr Relat Cancer. 2001;8:83–96.CrossRefPubMedGoogle Scholar
  14. Li Q, Tang Y, Cheng X, Ji J, Zhang J, Zhou X. EGFR protein expression and gene amplification in squamous intraepithelial lesions and squamous cell carcinomas of the cervix. Int J Clin Exp Pathol. 2014;7:733–41.PubMedPubMedCentralGoogle Scholar
  15. Luetteke NC, Qiu TH, Fenton SE, Troyer KL, Riedel RF, Chang A, et al. Targeted inactivation of the EGF and amphiregulin genes reveals distinct roles for EGF receptor ligands in mouse mammary gland development. Development. 1999;126:2739–50.PubMedGoogle Scholar
  16. Roskoski Jr R. The ErbB/HER family of protein-tyrosine kinases and cancer. Pharmacol Res. 2014;79:34–74.  https://doi.org/10.1016/j.phrs.2013.11.002.CrossRefPubMedGoogle Scholar
  17. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba II, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst. 2005;97:339–46.  https://doi.org/10.1093/jnci/dji055.CrossRefPubMedGoogle Scholar
  18. Taylor SR, Markesbery MG, Harding PA. Heparin-binding epidermal growth factor-like growth factor (HB-EGF) and proteolytic processing by a disintegrin and metalloproteinases (ADAM): a regulator of several pathways. Semin Cell Dev Biol. 2014;28:22–30.  https://doi.org/10.1016/j.semcdb.2014.03.004.CrossRefPubMedGoogle Scholar
  19. Ullrich A, Coussens L, Hayflick JS, Dull TJ, Gray A, Tam AW, et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells. Nature. 1984;309:418–25.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG 2018

Authors and Affiliations

  • Brian P. Ceresa
    • 1
    Email author
  • Julie A. Gosney
    • 1
  • Nicole M. Jackson
    • 1
  • Jamie S. Rush
    • 1
  1. 1.Department of Pharmacology and ToxicologyUniversity of LouisvilleLouisvilleUSA